Lenograstim

Lenograstim is a recombinant granulocyte colony-stimulating factor which functions as a immunostimulator. It is developed by Ligand Pharmaceuticals (LGND) under the brand name Graslopin.

Lenograstim has been investigated as a possible adjunctive treatment for severe sepsis and found to be ineffective.